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ABSTRACT 
 
Background: Recent studies reported an increased risk of suicidality in behavioral variant Fronto-
temporal Dementia (bvFTD). Aim of the study was to determine the prevalence of suicidal ideation 
and attempts in bvFTD patients, evaluating possible risk factors for suicidality.  
Methods: Risk of suicide was assessed using the Scale for Suicide Ideation (SSI) in 35 bvFTD pa-
tients and 25 controls.  
Results: According to SSI, 40% of bvFTD patients had suicidal ideation in comparison to 8% of 
controls (p=.009). Four bvFTD patients have attempted suicide versus none control (p=.006). 
BvFTD patients with suicide risk showed higher levels of anxiety, depression, stress and hopeless-
ness than patients without suicide risk (p<.001). Patients who attempted suicide were younger, and 
had a longer disease duration than those with only suicide ideation. Intriguingly, 40% of patients 
with parkinsonism presented high level of suicide ideation. 
Conclusions: Our findings show that bvFTD patients have a high risk of suicide. Additional studies 
in larger population are needed to confirm our results. 
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INTRODUCTION 
  
     The term Frontotemporal Dementia (FTD) encompasses a spectrum of neurodegenerative dis-
eases clinically characterized by a progressive decline in both behavior and language, related to 
deposition of misfolded proteins in frontal and temporal lobes. Behavioral variant frontotemporal 
dementia (bvFTD), semantic dementia (SD), and progressive non-fluent aphasia (PNFA) are the 
main clinical subtypes of FTD 1. 
  
     FTD is the second cause of presenile dementia, and bvFTD represents the most frequent subtype 
2, 3. This form is clinically characterized by prominent behavioral disturbances, including disinhibi-
tion, impulsivity, perseverations and loss of empathy, that are associated with deterioration of social 
conduct and impairment of cognition 1,4.  Recently, a complex and intriguing relationship between 
bvFTD and several psychiatric disorders has been described. Psychiatric symptoms may represent 
the first clinical signs of bvFTD, even several years before the onset of behavioral and cognitive 
symptoms 5. 
 
     In patients with overall dementia, the risk of suicide is generally considered low 6-8. However, a 
growing body of research suggests that mood changes, severity of cognitive impairment, and 
awareness of disease, may lead patients with different forms of dementia to be more vulnerable to 
suicidal behavior 8-12.  To date, literature is scarce about the suicide risk in patients with bvFTD. In 
2012, a first case report described a patient with bvFTD who committed suicide a few months after 
the diagnosis 13. Subsequently, a retrospective study reported a higher risk of suicidal behavior in 
bvFTD patients when compared to controls 14. At present, prevalence and risk factors for suicide 
have not been adequately investigated in bvFTD.  
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         Thence, primary aim of our study was to determine the prevalence of both suicidal ideation 
and suicidal attempts in a cohort of patients with bvFTD, according to a case-control strategy. A 
secondary aim was to evaluate the possible neuropsychological and neuropsychiatric risk factors 
correlated with suicidality.   
 
METHODS  
Participants 
     Thirty-five patients with a diagnosis of probable bvFTD  (18 men, 17 women; mean age± SD: 
70.1± 6.3 years) attending the Aging Brain and Memory Clinic of the Department of Neuroscience 
“Rita Levi Montalcini”, University of Torino, Italy, were recruited for the study. The diagnosis of 
bvFTD was performed according to Rascovsky et al. criteria 15.   
Patients underwent extensive clinical, neuropsychological, and neuroimaging investigations (brain 
MRI and 18-FDG PET). The clinical diagnosis was supported by CSF biomarkers (beta amyloid, 
total tau, and phosphorylated tau), in order to exclude Alzheimer’s disease pathology. Patients were 
screened for genetic variants in the major FTD-related genes (MAPT, GRN, and C9orf72) 19. A 
group of 25 healthy age- and education-matched subjects (8 men, 17 women; mean age ± SD: 
68.1±7.4 years) served as controls. Patients were excluded from the study if they had (a) an Ano-
sognosia Questionnaire-Dementia (AQ-D) 16 score ≥ 32, (b) a Mini Mental State Examination 
(MMSE) 17 score < 24, and (c) a Token Test (TT) 18 score  < 26.5. 
 
Written informed consent was obtained from all participants and the study was approved by the 
Hospital Ethics Committee. 
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Assessment of suicidality  
    Suicide risk was measured using the Scale for Suicide Ideations (SSI) 20, as suggested by the Ital-
ian Society of Psychiatry [www.psichiatrica.it]. SSI is a 19-item semistructured interview per-
formed by a clinician, based on patient’s answers, evaluating self-destructive and suicide thoughts 
within the last week period. In addition, data on previous suicide attempts are collected by the test. 
In details, SSI consists of five screening domains: three items exploring the wish to live or die, and 
two items evaluating the desire to attempt suicide. Each item consists of a 3-point scale, ranging 
from 0 to 2, to quantify suicidal intensity. Fourteen additional questions are administered if the sub-
jects report any active or passive thoughts to commit suicide. Answers include duration and fre-
quency of ideation, sense of control over making an attempt, number of deterrents, and amount of 
actual preparation for a contemplated attempt. The overall score ranges from 0 to 38 and, according 
to literature, a score ≥ 6 has been used as threshold for suicidal ideation 21,22. Suicide attempt refers 
to potentially self-injurious behavior thought and performed with the purpose to kill oneself.  
 
Neuropsychological Assessment   
       Global cognitive impairment was assessed through Mini Mental State Examination (MMSE) 17, 
Clinical Dementia Rating Scale (CDR) 23, and Frontal Assessment Battery (FAB) 24. Other cogni-
tive domains were also investigated: attention and executive functions with Trail Making Test 
(TMT) 25,26, verbal learning and memory with Rey 15 Words Auditory Learning Test (RAVLT) 27 
and language comprehension with TT 18,25. In addition, Reading the Mind in the Eyes Test (RMET) 
has been used to evaluate the ability to recognize the mental state of others using the expressions of 
the eyes 28,29. Patients’ awareness of disease was assessed using the AQ-D scale 16. Finally, autono-
my in daily living was estimated with both Activities of Daily Living (ADL) 30 and the Instrumental 
Activities of Daily Living Scale (IADL) 31.  
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Neuropsychiatric Assessment 
     Each group underwent specific questionnaires on behavioral and mood changes. Apathy was as-
sessed with Apathy Evaluation Scale-Clinician Version (AES-C) 32, depression was examined with 
Hamilton Depression Rating Scale (HDR-S) 33, anxiety and stress were evaluated with Hamilton 
Anxiety Rating Scale (HAR-S) 34 and Perceived Stress Scale (PSS) 35. Finally, Barratt Impulsive-
ness Scale (BIS-11) 36 and Beck’s Hopelessness Scale (BHS) 37 were also used to evaluate patient’s 
impulsiveness and hopelessness. 
 
Statistical Analysis  
     All data were analyzed using SPSS Version 21.0 for Windows (IBM SPSS Statistics, Inc, Chi-
cago, IL, USA). Demographic and clinical variables were compared using T-test and χ2. Neuropsy-
chological and neuropsychiatric characteristics were analyzed using T-test and multivariate analysis 
of variance. Pearson’s rho with Bonferroni correction was used to evaluate the correlation between 
suicidal ideation and performance on the neuropsychological and neuropsychiatric tests. The signif-
icance level was set at p<.05 for all analyses, and p<.01 for Bonferroni correction. 
 
RESULTS  
Assessment of suicidality  
     Demographic and clinical characteristics of patients and controls are summarized in table 1. Ac-
cording to SSI scale, 40% of bvFTD patients showed suicide ideation, in comparison with 8.0% of 
controls (p= .009). Subsequently, according to the obtained scores, all the subjects involved in the 
study were divided into two different groups: A. subjects with risk of suicide (SR), and B. subjects 
without risk of suicide (NS).  
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When looking at overall bvFTD group, fourteen bvFTD patients had a risk of suicide (bvFTD-SR), 
and twenty-one bvFTD patients showed no suicide risk (bvFTD-NS). In the subgroup of bvFTD at 
risk of suicide, 10 patients showed a suicide ideation alone (71.4%), whereas four patients in addi-
tion to suicidal ideation, also had attempted suicide (28.6%).  In details, three patients with bvFTD 
had attempted suicide with a non-fatal self-poisoning, while one bvFTD patient tried to defenestrate 
himself. When bvFTD patients attempted suicide, they were not taking any L-dopa or dopaminergic 
treatments. In control group, according to the SSI, two controls (8%) had a risk of suicide (Cont-
SR), whereas the remaining subjects showed no suicide risk (Cont-NS).  
BvFTD patients who attempted suicide showed a higher global SSI score in comparison with those 
who presented suicidal ideation alone (p< .001). No differences were found in global SSI scores 
between males and females patients with bvFTD at risk of suicide.  
 
Neuropsychological Assessment   
     The overall group of bvFTD patients showed higher levels of functional and cognitive impair-
ment (p<.005) and were more apathetic and impulsive (p<.001) when compared with controls, as 
expected. Interestingly, in the bvFTD group, no differences in the neuropsychological characteris-
tics were found when comparing bvFTD patients at suicide risk and bvFTD patients with no suicide 
risk (Table 2).   
 
Neuropsychiatric Assessment 
    Using multivariate analysis for the neuropsychiatric data, patients with bvFTD presented higher 
levels of apathy, impulsivity and hopelessness (p< .001) when compared with controls. In the 
bvFTD group, patients at suicide risk showed higher scores in depression, anxiety, stress, and hope-
lessness (p<.001) in comparison with bvFTD patients with no suicide risk (Fig. 1).   
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Clinical characteristics  
     Evaluating the clinical characteristics of bvFTD patients, we observed that the subjects who at-
tempted suicide were younger (p<.05), and had a longer duration of the disease (p=.007) than 
bvFTD patients with only suicide ideation. In addition, gender and education did not influence the 
suicide risk in bvFTD.  
 
In the overall bvFTD group, seven out of 35 patients showed parkinsonism, mainly presenting with 
bradykinesia and axial rigidity. Notably, bvFTD patients with extrapyramidal signs had higher level 
of suicide ideation (OR= 15; 95% CI: 1.55-145.23, p=.019) than remaining patients.  
 
In this dataset of patients with bvFTD, one subject carried a missense mutation in GRN gene and 
one an expansion in C9orf72 gene. However, we do not detect any clear link between suicide risk 
and mutations in known FTD-related genes due to the paucity of patients with mutations.  
 
DISCUSSION 
     To the best of our knowledge, this is the first study evaluating both the suicidal behavior and the 
suicidal ideation in patients with behavioral variant frontotemporal dementia. Our findings showed 
that patients with bvFTD are at higher risk of suicide, since approximately 40% of our patients 
showed a suicidal ideation, and more than 10% attempted suicide. 
 
     Worldwide, suicidal behavior is a major cause of disability and the fifteenth cause of death ac-
cording to WHO reports 38. Globally, the lifetime prevalence of suicidal ideation is 9.2%, and of 
suicidal attempts is 2.7% 39. Therefore, investigating the prevalence of suicidal behavior as well as 
its neurobiological bases in patients with major neurocognitive disorders is paramount. The  
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risk of committing suicide in dementia is generally low, and suicide attempts are present in less than 
1% of patients 40,41. However, a recent study investigating the suicidal behavior in patients with 
FTD showed a higher risk of attempt of suicide in respect to controls 14. In our study, we confirmed 
these results in patients with bvFTD, the main subgroup of FTD, and we further showed that, not 
only the suicidal behavior, but also the suicidal ideation is high in these patients. It is of interest to 
note that, in our bvFTD population, the frequency of suicide behavior overlaps the one observed in 
Huntington’s disease, a neurodegenerative disease known to be associated with high risk of suicide 
42,43. Therefore, additional clinical and epidemiological studies are warranted in order to better in-
vestigate the risk of suicide in different neurodegenerative disorders.   
 
      In our study, bvFTD patients who have attempted suicide were younger and showed a longer 
duration of the disease than patients with only suicide ideation. Our findings are supported by a 
growing body of researches on suicidality in patients with dementia, reporting that young age is a 
risk factor for suicide behavior 9,11. Intriguingly, no association between gender and risk of suicide 
was found in our patients. This finding is in line with other research focused on suicide behavior in 
patients with neurodegenerative disorders, that not confirmed a higher tendency of suicidality in 
females 44. Recently, a case-control study on neurological disorders and suicide attempts showed 
that males with neurological diseases had a higher risk of attempting suicide than female patients 45. 
Therefore, further studies assessing the risk of suicide in patients with chronic neurological disor-
ders  according to gender are needed.  
 
Psychological aspects as anxiety and depression related to the diagnosis of a neurodegenerative dis-
order at an earlier age could drive suicidal behavior 11,12.  In our patients, risk factors for suicide in-
clude depression, anxiety, stress, and hopelessness. Since no therapies for the disease are currently 
available, bvFTD patients may experience an elevated stress and a sense of hopelessness for their 
future, leading to suicidal ideations. 
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     Neurobiological bases of suicidal behavior have been investigated only in recent years. Some 
studies suggested a role for the prefrontal regions in suicide 46. Post-mortem studies reported a re-
duction of presynaptic serotonin transporter sites in the prefrontal cortex, including the inferior 
frontal gyrus and the orbitofrontal cortex 47, brain areas typically involved in the pathogenesis of 
bvFTD. In addition, an increased in 5-HT1A binding was found in these regions, suggesting that the 
serotonergic dysfunction in suicide victims might be due to gene expression changes in dorsal and 
ventral regions of the prefrontal cortex 47. Finally, reduced concentrations of the serotonin metabo-
lite 5-hydroxyindoleacetic acid in the cerebrospinal fluid are associated with suicidal behavior in 
patients with depressive disorders and schizophrenia 48. All these findings support the role of the 
serotoninergic system in the pathogenesis of suicide behavior. 
      
       In our study, approximately 20% of the overall patients presented extrapyramidal signs, that is  
consistent with previously reported on the prevalence of parkinsonism in bvFTD 4.  Intriguingly, 
we observed that 40% of bvFTD patients with extrapyramidal signs showed higher level of suicide 
ideation than patients without parkinsonism. A recent case report described a suicide attempt in a 
patient with bvFTD with parkinsonian symptoms 13. These clinical findings could be of importance 
for clinicians treating these patients. This could also suggest an involvement of subcortical regions 
and basal ganglia in the risk of suicide. In literature, suicidal ideations have been reported to occur 
in approximately in 23% of patients with Parkinson’s disease 49. In addition, there are some evi-
dences in depressed suicide victims for a reduced dopamine turnover in the nucleus accumbens, 
caudate, and putamen 50. Furthermore, gene polymorphisms of the dopaminergic system have been 
reported to be involved in the biological susceptibility to suicide 51. Finally, a recent study showed 
that a haplotype in the dopamine receptor DRD2 gene is involved in suicidal behaviour in alcohol 
dependent subjects 52. Further investigations on the genetic susceptibility of suicide are therefore 
suggested in bvFTD patients.  
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     Finally, we suggest that suicide risk should be considered when evaluating patients with bvFTD, 
in particular in young age. Suicide ideation and attempts are strongly predictive of suicide deaths, 
but the risk of suicide in patients with dementias other than Alzheimer’s disease has often been un-
derestimated. Therefore, this study can have several potential clinical implications. First, a better 
understanding of risk factors associated with suicidal behavior in patients with bvFTD can increase 
the use of routine suicide evaluations. Secondly, an early identification of subjects who have suicid-
al ideation can help the clinicians to suggest psychological supports and to prescribe more effective 
individualized pharmacological therapies. In schizophrenia, there are some evidences that the typi-
cal antipsychotic drugs, associated or not with antidepressants, as well as the atypical neuroleptic 
drugs as clozapine, have an effect on suicidal behavior and reduce the risk of suicide 53. This thera-
peutic approach could also be applied to patients with bvFTD.  
 
     Our study has some limitations that deserve to be mentioned. First, the study population is rela-
tively small; however, the subjects recruited for the study have been extensively investigated in or-
der to exclude any other forms of dementia. Secondly, our work involves only bvFTD and does not 
capture the language forms of FTD. Previously, in patients with semantic dementia has been report-
ed that the risk of committing suicide is particularly high along with an accompanying awareness of 
their cognitive impairment 14. Contrariwise, a previous retrospective study on frontotemporal lobar 
degeneration reported that all the patients with suicidal behavior had the behavioral variant of FTD 
14. Third, our control population is unbalanced in term of gender. Notwithstanding, in our controls 
the prevalence of suicide ideation overlaps that reported in WHO findings 38. Fourth, in our study 
bvFTD patients present a lower level of education in respect to controls. However, in Italian popu-
lation, the attainment of high level of education is associated with a greater risk of suicide, thence 
the lower level of schooling in bvFTD may not have influenced the suicide ideation 54. Fifth in our 
study, suicide risk was assessed using the SSI as suggested by Italian psychiatric guidelines, and the 
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use of combined suicide scales might provide additional clinical data. Finally, the majority of the 
subjects involved in the study are aware of their disorder. In literature, it is unclear if a preserved 
insight potentially increases the risk of suicidal behavior in patients with neurodegenerative disor-
ders. 
 
     In conclusion, our data showed that patients with bvFTD are at high risk for suicide. Additional 
studies are needed in order to further investigate the suicide risk in bvFTD, and to elucidate the un-
derlying neurobiological and neurocognitive mechanisms.   
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TABLE 1.  Demographic characteristics of patients with bvFTD and controls. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations:  M= male; F= female 
 
 
 
 
 
 
 
 
 
 
 
 bvFTD Controls 
Gender (M/F) 18/17 8/17 
Age (yrs; mean ± SD) 70.14 ± 6.32 68.12 ± 7.44 
   
Education   
8 yrs 62.86% (22) 32.00% (8) 
 
13 yrs 25.71% (9) 40.00% (10) 
 
>13 yrs 11.43% (4) 28.00% (7) 
 
Onset of disease (yrs) 65.00 ± 7.82 - 
Duration of disease (yrs) 4.08 ± 3.27 - 
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TABLE  2.  Neuropsychological, Neuropsychiatric and Functional assessment synopsis of patients 
with bvFTD, according to the presence of the suicide risk. 
 
Abbreviations: bvFTD-SR = bvFTD patients with risk of suicide; bvFTD-NS = bvFTD without risk of suicide;  
MMSE= Mini-Mental State Examination; CDR= Clinical Dementia Rating Scale; FAB= Frontal Assessment Battery; 
TMT= Trial Making Test; RAVLT= Rey 15 Words Auditory Learning Test,; TT= Token Test; RMET = Reading the 
Mind in the Eyes test; AES-C= Apathy Evaluation Scale-Clinician Version; HDR-S= Hamilton Depression Rating 
Scale; HAR-S= Hamilton Anxiety Rating Scale; PSS= Perceived Stress Scale; BIS-11= Barratt Impulsiveness Scale; 
BHS= Beck’s Hopelessness Scale; AQ-D= Awareness Questionnaire Disease, ADL= Activity of Daily Living Scale; 
IADL= Instrumental Activity of Daily Living Scale. All data are presented as mean ± SD. 
 
 
 
 
 bvFTD-SR  bvFTD-NS p value 
MMSE 24.1 ± 3.4 23.7 ± 2.8 .685 
CDR 1.0 ± 0.7 1.1 ± 0.5 .858 
FAB 10.7 ± 3.6 10.9 ± 3.2 .881 
TMT-A 121.9 ± 124.1 103.4 ± 76.9 .755 
TMT-B 312.7 ± 137.9 290.8 ± 174.1 .706 
TMT B-A 232.2 ± 130.9 201.3 ± 149.8 .624 
RAVLT  21.3 ± 7.7 22.3 ± 6.7 .725 
TT 33.0 ± 2.4 32.1 ± 2.6 .579 
RMET 16.6 ± 4.1 18.0 ± 5.7 .349 
AES-C 13.9±12.3 23.7±18.7 .940 
HDR-S 26.4±9.0 11.5±5.5   .000* 
HAR-S 24.6±7.5 10.1±5.7   .000* 
PSS 27.6±3.2 16.1±5.2   .000* 
BIS-11 78.4±8.1 73.1±13.0 .188 
BHS 15.5±4.7 8.6±5.1   .000* 
AQ-D -2.5 ± 10.4 4.3 ± 9.0 .075 
ADL 4.8 ± 1.5 5.7 ± 5.0 .070 
IADL 5.2 ± 2.4 5.0 ± 2.2 .754 
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Figure 1. Levels of hopelessness, impulsivity, depression, apathy, anxiety, and stress in patients 
with bvFTD. Data are presented as means ± SD of subjects’ scores in questionnaires on behavioral 
and mood changes, according to the presence of suicide risk. bvFTD patients with risk of suicide 
(bvFTD-SR) show higher levels of hopelessness, depression, anxiety, and stress than bvFTD with-
out risk of suicide (bvFTD-NS). * p < .01.  
Abbreviations:  BHS= Beck’s Hopelessness Scale; BIS-11= Barratt Impulsiveness Scale; HDR-S= Hamilton Depres-
sion Rating Scale; AES-C= Apathy Evaluation Scale-Clinician Version; HAR-S= Hamilton Anxiety Rating Scale; 
PSS= Perceived Stress Scale. 
 
 
 
 
 
